` OCX (OncoCyte Corp) vs S&P 500 Comparison - Alpha Spread

OCX
vs
S&P 500

Over the past 12 months, OCX has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +13% growth.

Stocks Performance
OCX vs S&P 500

Loading
OCX
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
OCX vs S&P 500

Loading
OCX
S&P 500
Difference
www.alphaspread.com

Performance By Year
OCX vs S&P 500

Loading
OCX
S&P 500
Add Stock

Competitors Performance
OncoCyte Corp vs Peers

S&P 500
OCX
ABBV
AMGN
GILD
VRTX
Add Stock

OncoCyte Corp
Glance View

Market Cap
90.4m USD
Industry
Biotechnology

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. The company is headquartered in Irvine, California and currently employs 110 full-time employees. The company went IPO on 2015-12-30. The firm is focused on developing and commercializing proprietary tests, initially offered as laboratory-developed tests (LDTs), to serve unmet medical needs across the cancer care continuum. The Company’s products include DetermaRx, DetermaIO, and DetermaCNI. DetermaRx is a commercialized predictive molecular test for early-stage adenocarcinoma of the lung. This gene expression-based test provides information that a physician can use to identify early-stage, surgically resected patients with Stage I and IIA non-squamous non-small cell lung cancer (NSCLC). DetermaIO is developed to identify patients to respond to immunotherapy drugs. Its predictive biomarkers, including PD-L1 and Tumor Mutational Burden to predict, which patients responds to immunotherapy. DetermaCNI is a tumor-informed tests that are on market for treatment monitoring as well as blood-only targeted panels.

OCX Intrinsic Value
4.5 USD
Undervaluation 30%
Intrinsic Value
Price
Back to Top